Bio-Techne Co. (NASDAQ:TECH) Stock Holdings Reduced by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC lowered its position in Bio-Techne Co. (NASDAQ:TECH) by 2.1% during the third quarter, HoldingsChannel.com reports. The firm owned 10,024 shares of the biotechnology company’s stock after selling 214 shares during the quarter. Rice Hall James & Associates LLC’s holdings in Bio-Techne were worth $801,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. First City Capital Management Inc. lifted its position in shares of Bio-Techne by 6.2% in the first quarter. First City Capital Management Inc. now owns 3,185 shares of the biotechnology company’s stock worth $224,000 after buying an additional 185 shares during the last quarter. Empirical Finance LLC lifted its position in shares of Bio-Techne by 5.2% in the first quarter. Empirical Finance LLC now owns 3,957 shares of the biotechnology company’s stock worth $279,000 after buying an additional 195 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of Bio-Techne by 12.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,917 shares of the biotechnology company’s stock worth $137,000 after buying an additional 205 shares during the last quarter. Mather Group LLC. lifted its position in shares of Bio-Techne by 51.5% in the third quarter. Mather Group LLC. now owns 612 shares of the biotechnology company’s stock worth $49,000 after buying an additional 208 shares during the last quarter. Finally, Bleakley Financial Group LLC lifted its position in shares of Bio-Techne by 6.0% in the third quarter. Bleakley Financial Group LLC now owns 3,773 shares of the biotechnology company’s stock worth $302,000 after buying an additional 214 shares during the last quarter. Institutional investors and hedge funds own 98.95% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on TECH shares. Benchmark reissued a “buy” rating and set a $95.00 price objective on shares of Bio-Techne in a research report on Tuesday, August 13th. Robert W. Baird boosted their price objective on Bio-Techne from $82.00 to $84.00 and gave the stock an “outperform” rating in a research report on Thursday. StockNews.com raised Bio-Techne from a “hold” rating to a “buy” rating in a research report on Friday. Royal Bank of Canada cut their price objective on Bio-Techne from $72.00 to $70.00 and set a “sector perform” rating for the company in a research report on Thursday, August 8th. Finally, Scotiabank boosted their price objective on Bio-Techne from $83.00 to $88.00 and gave the stock a “sector outperform” rating in a research report on Thursday. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.78.

Bio-Techne Trading Up 2.1 %

TECH stock opened at $75.31 on Friday. Bio-Techne Co. has a 1-year low of $52.99 and a 1-year high of $85.57. The firm has a market cap of $11.95 billion, a P/E ratio of 80.12, a P/E/G ratio of 5.33 and a beta of 1.28. The business’s 50 day moving average is $73.69 and its 200-day moving average is $74.53. The company has a current ratio of 4.56, a quick ratio of 2.75 and a debt-to-equity ratio of 0.14.

Bio-Techne (NASDAQ:TECH) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.49 EPS for the quarter, meeting analysts’ consensus estimates of $0.49. The firm had revenue of $306.10 million for the quarter, compared to analyst estimates of $306.49 million. Bio-Techne had a return on equity of 12.76% and a net margin of 12.86%. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same period last year, the company earned $0.56 EPS. Equities analysts anticipate that Bio-Techne Co. will post 1.7 earnings per share for the current fiscal year.

Bio-Techne Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, November 22nd. Stockholders of record on Monday, November 11th will be paid a $0.08 dividend. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date is Friday, November 8th. Bio-Techne’s dividend payout ratio (DPR) is currently 34.04%.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.